{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:49:43Z","timestamp":1790419783829,"version":"4.1.0"},"reference-count":123,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. MPN are characterized by mutations in three driver genes (JAK2, CALR and MPL) and by a state of chronic inflammation. Notably, MPN patients experience increased risk of thrombosis, disease progression, second neoplasia and evolution to acute leukemia. Extracellular vesicles (EVs) are a heterogeneous population of microparticles with a role in cell-cell communication. The EV-mediated cross-talk occurs via the trafficking of bioactive molecules such as nucleic acids, proteins, metabolites and lipids. Growing interest is focused on EVs and their potential impact on the regulation of blood cancers. Overall, EVs have been suggested to orchestrate the complex interplay between tumor cells and the microenvironment with a pivotal role in \u201ceducation\u201d and \u201ccrafting\u201d of the microenvironment by regulating angiogenesis, coagulation, immune escape and drug resistance of tumors. This review is focused on the role of EVs in MPN. Specifically, we will provide an overview of recent findings on the involvement of EVs in MPN pathogenesis and discuss opportunities for their potential application as diagnostic and prognostic biomarkers.<\/jats:p>","DOI":"10.3390\/cells10092316","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T10:59:12Z","timestamp":1630925952000},"page":"2316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: \u201cCrafting\u201d a Microenvironment That Matters"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-201X","authenticated-orcid":false,"given":"Lucia","family":"Catani","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, Institute of Hematology \u201cSer\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, Institute of Hematology \u201cSer\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41375-021-01170-z","article-title":"Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms","volume":"35","author":"Guy","year":"2021","journal-title":"Leukemia"},{"key":"ref_2","first-page":"2992","article-title":"Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms","volume":"6","author":"Reeves","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hoc.2020.11.006","article-title":"Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms","volume":"35","author":"Schafer","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Brabrand, M., and Frederiksen, H. (2020). Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers, 12.","DOI":"10.3390\/cancers12103061"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1097\/HS9.0000000000000578","article-title":"Functional Consequences of Mutations in Myeloproliferative Neoplasms","volume":"5","author":"Constantinescu","year":"2021","journal-title":"Hemasphere"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hoc.2020.11.005","article-title":"Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms","volume":"35","author":"Shallis","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-020-04287-w","article-title":"Is there a gender effect in polycythemia vera?","volume":"100","author":"Palandri","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Karantanos, T., Jain, T., Moliterno, A.R., Jones, R.J., and DeZern, A.E. (2021). Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052595"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of Myeloproliferative Neoplasms","volume":"35","author":"Szybinski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"Oncotargets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Guijarro-Hernandez, A., and Vizmanos, J.L. (2021). A Broad Overview of Signaling in pH-Negative Classic Myeloproliferative Neoplasms. Cancers, 13.","DOI":"10.3390\/cancers13050984"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.hoc.2020.11.003","article-title":"The Microenvironment in Myeloproliferative Neoplasms","volume":"35","author":"Ramanathan","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., and Carubbi, C. (2020). Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 9.","DOI":"10.3390\/cells9092136"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Di Battista, V., Bochicchio, M.T., Giordano, G., Napolitano, M., and Lucchesi, A. (2021). Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020561"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-030-49270-0_7","article-title":"The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche)","volume":"1273","author":"Zhan","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-018-0349-9","article-title":"Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera","volume":"33","author":"Fowles","year":"2019","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21972","article-title":"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","article-title":"Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation","volume":"40","author":"Cacemiro","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: WheTher. to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nasillo, V., Riva, G., Paolini, A., Forghieri, F., Roncati, L., Lusenti, B., Maccaferri, M., Messerotti, A., Pioli, V., and Gilioli, A. (2021). Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041906"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.humimm.2015.09.010","article-title":"Natural killer cells in patients with polycythemia vera","volume":"76","author":"Sanchez","year":"2015","journal-title":"Hum. Immunol."},{"key":"ref_30","first-page":"136","article-title":"Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity","volume":"12","author":"Gersuk","year":"1993","journal-title":"Nat. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1521-6616(02)00046-3","article-title":"Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis","volume":"106","author":"Briard","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-alpha in myeloproliferative neoplasm","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2018058","DOI":"10.4084\/mjhid.2018.058","article-title":"The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes their Osteoclasts more Susceptible to JAK2 Inhibition","volume":"10","author":"Spanoudakis","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1782575","DOI":"10.1080\/2162402X.2020.1782575","article-title":"The role of circulating monocytes and JAK inhibition in the infectious- driven inflammatory response of myelofibrosis","volume":"9","author":"Barone","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","article-title":"Longitudinal Cytokine Profiling Identifies GRO-alpha and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia","volume":"4","author":"Obro","year":"2020","journal-title":"Hemasphere"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in polycythemia vera: Clinical and molecular correlates","volume":"92","author":"Barraco","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstrom","year":"2016","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms","volume":"31","author":"Holmstrom","year":"2017","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstrom","year":"2018","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms","volume":"9","author":"Bozkus","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2016-03-704577","article-title":"Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis","volume":"128","author":"Massa","year":"2016","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid malignancies and the microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12929-019-0533-x","article-title":"Basics and applications of tumor-derived extracellular vesicles","volume":"26","author":"Tai","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1038\/s41375-020-01041-z","article-title":"Extracellular microvesicles\/exosomes: Discovery, disbelief, acceptance, and the future?","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"key":"ref_52","first-page":"3703","article-title":"Purification, characterization and biological significance of tumor-derived exosomes","volume":"25","author":"Koga","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0030-1267042","article-title":"Platelet- and megakaryocyte-derived microparticles","volume":"36","author":"Flaumenhaft","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2008-06-163832","article-title":"Megakaryocyte-derived microparticles: Direct visualization and distinction from platelet-derived microparticles","volume":"113","author":"Flaumenhaft","year":"2009","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1684862","DOI":"10.1080\/20013078.2019.1684862","article-title":"Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: An ISEV position paper arising from the ISEV membranes and EVs workshop","volume":"8","author":"Russell","year":"2019","journal-title":"J. Extracell Vesicles"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Pezzicoli, G., Tucci, M., Lovero, D., Silvestris, F., Porta, C., and Mannavola, F. (2020). Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186543"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/acs.jproteome.8b00647","article-title":"Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs","volume":"18","author":"Jimenez","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2019.12.007","article-title":"Large extracellular vesicles: Size matters in tumor progression","volume":"51","author":"Ciardiello","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","article-title":"The exosome journey: From biogenesis to uptake and intracellular signalling","volume":"19","author":"Gurung","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1096\/fba.2020-00127","article-title":"The ins and outs of microvesicles","volume":"3","author":"Clancy","year":"2021","journal-title":"FASEB Bioadv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1242\/jcs.222406","article-title":"New insights into extracellular vesicle biogenesis and function","volume":"132","author":"Latifkar","year":"2019","journal-title":"J. Cell Sci."},{"key":"ref_62","first-page":"1672","article-title":"The role of lipids in exosome biology and intercellular communication: Function, analytics and applications","volume":"92","year":"2021","journal-title":"Traffic"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Corbeil, D., Santos, M.F., Karbanova, J., Kurth, T., Rappa, G., and Lorico, A. (2020). Uptake and Fate of Extracellular Membrane Vesicles: Nucleoplasmic Reticulum-Associated Late Endosomes as a New Gate to Intercellular Communication. Cells, 9.","DOI":"10.3390\/cells9091931"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2015.08.006","article-title":"Isolation and molecular characterization of extracellular vesicles","volume":"87","author":"Taylor","year":"2015","journal-title":"Methods"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1021\/pr501279t","article-title":"Mass-spectrometry-based molecular characterization of extracellular vesicles: Lipidomics and proteomics","volume":"14","author":"Kreimer","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2010.039743","article-title":"Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1","volume":"96","author":"Szczepanski","year":"2011","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.csbj.2020.09.027","article-title":"High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies","volume":"18","author":"Tanasi","year":"2020","journal-title":"Comput Struct Biotechnol J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cbin.11620","article-title":"Exosomes: Isolation, characterization, and biomedical applications","volume":"45","author":"Alzhrani","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Forte, D., Barone, M., Palandri, F., and Catani, L. (2021). The \u201cVesicular Intelligence\u201d Strategy of Blood Cancers. Genes, 12.","DOI":"10.3390\/genes12030416"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9863194","DOI":"10.1155\/2018\/9863194","article-title":"Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies","volume":"2018","author":"Laurenzana","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"110854","DOI":"10.1016\/j.biopha.2020.110854","article-title":"Communication between stromal and hematopoietic stem cell by exosomes in normal and malignant bone marrow niche","volume":"132","author":"Niazi","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"654023","DOI":"10.3389\/fphar.2021.654023","article-title":"Role of ATP in Extracellular Vesicle Biogenesis and Dynamics","volume":"12","author":"Lombardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s13046-019-1317-6","article-title":"Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation","volume":"38","author":"Ciardiello","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ebiom.2019.02.024","article-title":"Reprogramming of GBM microenvironment by large oncosomes: \u2018Traveling\u2019 V-ATPases are doing more than acidification","volume":"41","author":"Garnier","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1505403","DOI":"10.1080\/20013078.2018.1505403","article-title":"Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma","volume":"7","author":"Vagner","year":"2018","journal-title":"J. Extracell Vesicles"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1158\/0008-5472.CAN-16-2942","article-title":"MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer","volume":"77","author":"Minciacchi","year":"2017","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4161\/cc.26539","article-title":"Large oncosomes mediate intercellular transfer of functional microRNA","volume":"12","author":"Morello","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10456-015-9486-1","article-title":"PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells","volume":"19","author":"Fang","year":"2016","journal-title":"Angiogenesis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3324\/haematol.2017.183335","article-title":"Extracellular vesicles in the hematopoietic microenvironment","volume":"103","author":"Butler","year":"2018","journal-title":"Haematologica"},{"key":"ref_80","first-page":"2776","article-title":"Clinical relevance of extracellular vesicles in hematological neoplasms: From liquid biopsy to cell biopsy","volume":"27","author":"Trino","year":"2020","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-030-20315-3_11","article-title":"Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms","volume":"179","author":"Sankar","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_87","first-page":"69","article-title":"Polycythaemia vera: Molecular genetics, diagnostics and therapeutics","volume":"6","author":"Putter","year":"2021","journal-title":"Vox Sang."},{"key":"ref_88","first-page":"41","article-title":"Plasma-derived microparticles in polycythaemia vera","volume":"40","author":"Ahadon","year":"2018","journal-title":"Malays. J. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Fel, A., Lewandowska, A.E., Petrides, P.E., and Wisniewski, J.R. (2019). Comparison of Proteome Composition of Serum Enriched in Extracellular Vesicles Isolated from Polycythemia Vera Patients and Healthy Controls. Proteomes, 7.","DOI":"10.3390\/proteomes7020020"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2010.06.025","article-title":"Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms","volume":"126","author":"Duchemin","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1160\/TH12-11-0811","article-title":"Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation","volume":"109","author":"Tan","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MBC.0000000000000293","article-title":"Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: A single-centre experience","volume":"26","author":"Kissova","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3892\/ol.2017.6459","article-title":"Clinical significance of circulating microparticles in pH(-) myeloproliferative neoplasms","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12185-017-2302-5","article-title":"Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms","volume":"106","author":"Taniguchi","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1172\/JCI124566","article-title":"Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm","volume":"130","author":"Poisson","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and oTher. myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","article-title":"Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature","volume":"5","author":"Alimam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/HS9.0000000000000521","article-title":"Low-Risk Essential Thrombocythemia: A Comprehensive Review","volume":"5","author":"Robinson","year":"2021","journal-title":"Hemasphere"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"636675","DOI":"10.3389\/fonc.2020.636675","article-title":"Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia","volume":"10","author":"Tremblay","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.hoc.2021.01.003","article-title":"Unmet Need in Essential Thrombocythemia and Polycythemia Vera","volume":"35","author":"Kishtagari","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential Thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.thromres.2013.09.009","article-title":"Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders","volume":"132","author":"Connor","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.thromres.2010.08.002","article-title":"Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis","volume":"126","author":"Ternisien","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"Trappenburg","year":"2009","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.23590","article-title":"Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia","volume":"89","author":"Marchetti","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.3324\/haematol.2016.144279","article-title":"Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia","volume":"101","author":"Charpentier","year":"2016","journal-title":"Haematologica"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trsl.2017.02.001","article-title":"Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia","volume":"184","author":"Piccin","year":"2017","journal-title":"Transl. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41419-021-03743-3","article-title":"CircRNAs: Role in human diseases and potential use as biomarkers","volume":"12","author":"Verduci","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/cbin.11534","article-title":"Differential expression of circular RNAs in bone marrow-derived exosomes from essential thrombocythemia patients","volume":"45","author":"Wang","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100691","DOI":"10.1016\/j.blre.2020.100691","article-title":"A provider\u2019s guide to primary myelofibrosis: Pathophysiology, diagnosis, and management","volume":"45","author":"Garmezy","year":"2021","journal-title":"Blood Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.hoc.2020.11.004","article-title":"The Role of Megakaryocytes in Myelofibrosis","volume":"35","author":"Migliaccio","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Rumi, E., Trotti, C., Vanni, D., Casetti, I.C., Pietra, D., and Sant\u2019Antonio, E. (2020). The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238885"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hoc.2020.12.003","article-title":"Current Clinical Investigations in Myelofibrosis","volume":"35","author":"Venugopal","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1007\/s13277-015-3741-3","article-title":"High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders","volume":"36","author":"Caivano","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjh.15682","article-title":"Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis","volume":"185","author":"Barone","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01776-8","article-title":"Distinct profile of CD34(+) cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease","volume":"40","author":"Forte","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:56:20Z","timestamp":1760165780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":123,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cells10092316"],"URL":"https:\/\/doi.org\/10.3390\/cells10092316","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]}}}